Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

Dallas, TX & Quebec, Canada, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling a variety of men’s wellness products and services via a secure telemedicine platform, is pleased to announce that it has entered into an exclusive Master Distribution Agreement with Propre Energie, Inc., the developer of skincare brand Dermytol®, a clinically proven treatment designed to improve skin tone and reduce hyperpigmentation. Dermytol® is an advanced, plant-based formula developed to address dark spots, uneven skin tone, acne scars, and other pigmentation concerns. Unlike traditional skin treatments that may cause irritation or long-term damage, Dermytol® utilizes a proprietary blend of clinically validated ingredients, including canola phenolic acid, Camellia sinensis tea extract, evening primrose, and aloe vera. The patented formulation harnesses the melanin-reducing properties of canola extract, providing a safer and more stable alternative to conventional ingredients like hydroquinone and kojic acid. The efficacy of Dermytol® as a safe and effective skincare treatment was demonstrated in vitro, where it was tested against Kojic acid—a widely used skin lightening agent derived from fungi. At medium and high concentrations, Dermytol® was found to be more effective at reducing melanin production while being significantly less damaging to skin cells than Kojic acid. According to the study, this would make Dermytol® a superior option for individuals seeking a clinically backed solution for hyperpigmentation and overall skin health. The global skincare market is projected to reach approximately $218 billion by 2029, growing at a compound annual growth rate (CAGR) of 3.61% from 2025 to 2029. Within this expansive market, the plant-based skincare segment is experiencing significant growth. The global plant-based skincare products market, valued at $789.75 million in 2023, is expected to grow to $1.62 billion by 2033, reflecting a robust CAGR of 7.5% over the next decade. This surge is driven by consumer demand for natural, science-backed skincare solutions that offer visible results without compromising skin health. Consumers are increasingly prioritizing products that promote healthier, more sustainable options, driving the market for non-retinol skincare solutions. Dermytol®️ is poised to meet this demand with its innovative, clinically proven formulations, addressing a significant gap in the market for safe and effective solutions for hyperpigmentation, dark spots, and uneven skin tone Jacob Cohen, CEO of Mangoceuticals, Inc., expressed enthusiasm for the partnership, stating: “We are thrilled to add Dermytol®️ to our growing portfolio of high-performance wellness products. The demand for effective, natural skincare solutions is on the rise, and this collaboration allows us to bring a scientifically advanced product to market that aligns perfectly with our mission of delivering high-quality health and wellness solutions.” Peter Polimeneas, CEO of Propre Energie Inc., added: “This agreement is a significant milestone for Dermytol®️ as we expand into new markets with the support of a strong and experienced partner. Mangoceuticals’ expertise in digital marketing and e-commerce, combined with their dedication to quality, makes them the ideal distributor for our brand.” Through this agreement, Mangoceuticals secures exclusive rights to market, sell, and distribute Dermytol® across North and South America. The product will be available in both patch and cream formulations, offering versatile treatment options for consumers seeking to improve their skin’s radiance and overall health. Mangoceuticals aims to leverage its robust marketing and distribution infrastructure to accelerate Dermytol®’s penetration in key markets. About Propre Energie, Inc. Propre Energie Inc. is a Quebec-based company specializing in plant-based, non-retinol skincare solutions under the Dermytol®️ brand. With a focus on research and innovation, Propre Energie is dedicated to developing clinically proven, safe, and effective skincare products for individuals seeking healthier skin. About MangoRx MangoRx is focused on developing a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED), hair growth, hormone replacement therapies, and weight management. Interested consumers can use MangoRx’s telemedicine platform for a smooth experience. Prescription requests will be reviewed by a physician and, if approved, fulfilled and discreetly shipped through MangoRx’s partner compounding pharmacy and right to the patient’s doorstep. To learn more about MangoRx’s mission and other products, please visit www.MangoRx.com or on social media @Mango.Rx. Cautionary Note Regarding Forward-Looking Statements Certain statements made in this press release contain forward-looking information within the meaning of applicable securities laws, including within the meaning of the Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). These forward-looking statements represent the Company’s current expectations or beliefs concerning future events and can generally be identified using statements that include words such as “estimate,” “expects,” “project,” “believe,” “anticipate,” “intend,” “plan,” “foresee,” “forecast,” “likely,” “will,” “target” or similar words or phrases. These forward-looking statements are subject to risks, uncertainties and other factors, many of which are outside of the Company’s control which could cause actual results to differ materially from the results expressed or implied in the forward-looking statements, relating to, among other things: the investigation into, outcome of the investigation regarding, and potential lawsuits, claims and actions regarding, a potential stock manipulation scheme relating to the Company’s common stock following the Company’s recent reverse stock split; the outcome of certain outstanding legal matters, claims and allegations, the requirement that the Company spend cash and management’s resources on such matters, even if the Company ultimately prevails in such matters, risks associated with certain counterparties to lawsuits having significantly greater resources than us, settlements we may choose to enter into in the future and the terms thereof, and potential regulatory reviews, inquiries or lawsuits, which are brought about by claims made in private lawsuits; the review and evaluation of strategic transactions and their impact on shareholder value; the process by which the Company engages in evaluation of strategic transactions; the outcome of potential future strategic transactions and the terms thereof; the ability of the Company to raise funding, the terms of such funding, and dilution caused thereby; our ability to meet the continued listing requirements of Nasdaq; our ability to maintain the listing of our common stock on Nasdaq; our ability to commercialize our patent portfolio; our ability to obtain Comisión Federal para la Protección contra Riesgos Sanitarios for our ED product in Mexico, the costs thereof and timing associated therewith; our ability to obtain additional funding and generate revenues to support our operations; risks associated with our products which have not been, and will not be, approved by the U.S. Food and Drug Administration (“ FDA ”) and have not had the benefit of the FDA’s clinical trial protocol which seeks to prevent the possibility of serious patient injury and death; risks that the FDA may determine that the compounding of our products does not fall within the exemption from the Federal Food, Drug, and Cosmetic Act (“ FFDCA Act ”) provided by Section 503A; risks associated with related party relationships and agreements; the effect of data security breaches, malicious code and/or hackers; competition and our ability to create a well-known brand name; changes in consumer tastes and preferences; material changes and/or terminations of our relationships with key parties; significant product returns from customers, product liability, recalls and litigation associated with tainted products or products found to cause health issues; claims, lawsuits and litigation relating to our intellectual property, including allegations that our intellectual property infringes on the intellectual property of others, costs related to any such claims or lawsuits and resources required to expend in connection therewith; our ability to innovate, expand our offerings and compete against competitors which may have greater resources; our significant reliance on related party transactions and risks associated with related party relationships and agreements; the projected size of the potential market for our technologies and products; risks related to the fact that our Chairman and Chief Executive Officer, Jacob D. Cohen has significant voting control over the Company; risks related to the significant number of shares in the public float, our share volume, the effect of sales of a significant number of shares in the marketplace; dilution caused by recent and future offerings; conversion of outstanding shares of preferred stock and the rights and preferences thereof, the fact that we have a significant number of outstanding warrants to purchase shares of common stock and other convertible securities, the resale of which underlying shares have been registered under the Securities Act of 1933, as amended, dilution caused by exercises/conversions thereof, overhang related thereto, and decreases in the trading price of our common stock caused by sales thereof; our ability to build and maintain our brands; cybersecurity, information systems and fraud risks and problems with our websites; changes in, and our compliance with, rules and regulations affecting our operations, sales, marketing and/or our products; shipping, production or manufacturing delays; regulations we are required to comply with in connection with our operations, manufacturing, labeling and shipping; our dependency on third-parties to prescribe and compound our products; our ability to establish or maintain relations and/or relationships with third-parties; potential safety risks associated with our products, including the use of ingredients, combination of such ingredients and the dosages thereof; the effects of changing rates of inflation and interest rates, and economic downturns, including potential recessions, as well as macroeconomic, geopolitical, health and industry trends, pandemics, acts of war (including the ongoing Ukraine/Russian conflict and war in Israel) and other large-scale crises; our ability to protect intellectual property rights; our ability to attract and retain key personnel to manage our business effectively; overhang which may reduce the value of our common stock; volatility in the trading price of our common stock; and general consumer sentiment and economic conditions that may affect levels of discretionary customer purchases of the Company’s products, including potential recessions and global economic slowdowns. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this release are reasonable, we provide no assurance that these plans, intentions or expectations will be achieved. Consequently, you should not consider any such list to be a complete set of all potential risks and uncertainties. More information on potential factors that could affect the Company’s financial results is included from time to time in the “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and our Quarterly Report on Form 10-Q for the quarter September 30, 2024, and subsequent reports. These filings are available at www.sec.gov and at our website at https://www.mangoceuticals.com/sec-filings . All subsequent written and oral forward-looking statements attributable to the Company or any person acting on behalf of the Company are expressly qualified in their entirety by the cautionary statements referenced above. Other unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and takes no obligation to update or correct information prepared by third parties that are not paid for by the Company. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Follow MangoRx on social media: https://www.instagram.com/mango.rxhttps://x.com/mango_rxhttps://www.facebook.com/MangoRxOfficial FOR INVESTOR RELATIONS Mangoceuticals Investor RelationsEmail: investors@mangorx.com

Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol®️ Skincare Treatment Targeting Hyperpigmentation

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News